Brooks Laboratories Ltd (BROOKS) is currently trading at 62.99 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Brooks Laboratories Limited is a pharmaceutical manufacturing company specializing in the production of injectables, tablets, and dry syrups. It operates on a contract basis with major pharmaceutical clients. The company has two cGMP compliant manufacturing plants located in Baddi, Himachal Pradesh, and Vadodara, Gujarat. The Vadodara facility is notably approved by the European Medicine Agency, underlining its international quality standards. Due to strategic upgrades, Brooks Labs has enhanced its equipment and processes leading to substantial capacity improvements, especially the doubling of capacity for injectables at the Baddi plant. Brooks Labs partners with major pharmaceutical companies such as Zydus Cadila and Wockhardt and supplies critically needed products in the parental care segment across India. The company's Vadodara plant, recognized as the world's largest dedicated EU-certified facility, has enabled it to boost its presence and credentials in both domestic and international markets.

Over the past 52 weeks, Brooks Laboratories Ltd has traded between a low of ₹58.25 and a high of ₹165.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Brooks Laboratories Ltd has a market capitalization of approximately 184.31. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Brooks Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 8.64 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 184.31 Cr, Brooks Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Brooks Laboratories Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Brooks Laboratories Ltd is 8.64. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.